Symptoms of Kidney Cancer

Kidney cancer often remains asymptomatic in early stages and is frequently discovered incidentally during imaging for other reasons. When symptoms do occur, they may include:

Hematuria (Blood in Urine): The most common presenting symptom, occurring in approximately 40-60% of symptomatic patients. Urine may appear pink, red, or cola-colored. The bleeding may be visible (gross hematuria) or microscopic, and may be intermittent.

Flank Pain: Persistent dull ache or sharp pain in the side or lower back, typically unilateral. Pain may be caused by tumor stretching the renal capsule, invasion of surrounding structures, or obstruction from blood clots.

Palpable Abdominal Mass: A firm, non-tender mass may be felt in the flank or upper abdomen during physical examination. This finding alone is uncommon in the era of cross-sectional imaging.

Unintentional Weight Loss: Significant and unexplained weight loss exceeding 5% of body weight over 6-12 months, often accompanying other constitutional symptoms.

Fatigue and Malaise: Persistent tiredness, weakness, and lack of energy disproportionate to activity level. Cancer-related fatigue is often refractory to rest.

Fever: Intermittent low-grade fever not associated with infection. Approximately 20% of patients experience tumor-related fever due to cytokine production.

Anemia: Low red blood cell count causing pallor, weakness, shortness of breath on exertion, and dizziness. Occurs in approximately 30% of patients.

Hypertension: New-onset or worsening high blood pressure caused by renin secretion by the tumor or compression of the renal artery.

Varicocele: In males, acute onset of a left-sided varicocele that does not collapse when lying down may indicate a renal tumor obstructing the left testicular vein. This is a classic but uncommon sign.

Paraneoplastic Syndromes: Systemic effects of malignancy not related to direct tumor invasion include hypercalcemia (elevated blood calcium causing confusion, constipation, kidney stones), polycythemia (abnormally increased red blood cells), and Stauffer syndrome (non-metastatic hepatic dysfunction).

Lower Extremity Edema: Swelling of the legs due to tumor compression of the inferior vena cava or lymphatic obstruction.

The classic triad of flank pain, palpable mass, and hematuria occurs in fewer than 10% of cases and typically indicates locally advanced or metastatic disease. Any persistent or unexplained symptom warrants prompt urological evaluation.

Treatment Approaches for Kidney Cancer

Treatment for kidney cancer depends on the stage, tumor size, location, histological subtype, and the patient's overall health. At Guangzhou Fosun Chancheng Hospital, our multidisciplinary team develops personalized treatment plans using the latest evidence-based approaches:

Surgery: The mainstay of treatment for localized kidney cancer. Options include:

• Radical Nephrectomy: Complete removal of the affected kidney, adrenal gland, surrounding fatty tissue, and regional lymph nodes.
• Partial Nephrectomy (Nephron-Sparing Surgery): Removes only the tumor while preserving healthy kidney tissue. Preferred for small tumors (<4 cm) and selected larger tumors when technically feasible.
• Minimally Invasive Approaches: Laparoscopic and robotic-assisted surgery offer reduced pain, shorter hospital stays, and faster recovery compared to open surgery.

Ablation Therapy: For small tumors (<3 cm) in patients who are not surgical candidates. Techniques include radiofrequency ablation (RFA), cryoablation, and microwave ablation, which destroy cancer cells using heat or extreme cold.

Targeted Therapy: Drugs that block specific molecules involved in tumor growth and angiogenesis:

• Tyrosine Kinase Inhibitors (TKIs): Sunitinib, pazopanib, cabozantinib, axitinib, and lenvatinib target VEGF receptors and other kinases involved in tumor blood vessel formation.
• mTOR Inhibitors: Everolimus and temsirolimus inhibit the mTOR pathway regulating cell growth and proliferation.

Immunotherapy: Checkpoint inhibitors that activate the patient's immune system to recognize and attack cancer cells:

• PD-1/PD-L1 Inhibitors: Nivolumab and pembrolizumab block immune checkpoint proteins, unleashing T-cell-mediated antitumor responses.
• CTLA-4 Inhibitors: Ipilimumab enhances T-cell activation and proliferation.
• Combination Therapy: First-line regimens such as nivolumab plus ipilimumab (for intermediate/poor-risk disease) or axitinib plus pembrolizumab (for all risk groups) have shown superior overall survival compared to sunitinib alone.

Radiation Therapy: Primarily used for palliation of symptomatic bone metastases and brain metastases. Stereotactic body radiation therapy (SBRT) may be used for oligometastatic disease in selected patients.

Active Surveillance: For small renal masses (<2 cm) in elderly or comorbid patients, periodic monitoring with imaging (CT/MRI/ultrasound) rather than immediate intervention, with a low threshold for switching to active treatment if the tumor grows.

Cytoreductive Nephrectomy: Removal of the primary kidney tumor in the setting of metastatic disease, followed by systemic therapy, may benefit selected patients with good performance status.

Prognosis of Kidney Cancer

The prognosis of kidney cancer varies significantly based on stage at diagnosis, histological subtype, tumor grade, and patient performance status. Early detection and advances in treatment have substantially improved outcomes:

Survival by Stage:

• Stage I (Tumor 7 cm, confined to kidney): 5-year overall survival rate >90%. Surgical resection with negative margins is often curative. Recurrence rate after partial or radical nephrectomy is approximately 3-5% at 5 years.
• Stage II (Tumor >7 cm, confined to kidney): 5-year survival rate approximately 75-85%. Larger tumor size is associated with higher Fuhrman grade and increased risk of microvascular invasion.
• Stage III (Regional lymph node involvement, renal vein or vena cava tumor thrombus, or perinephric fat invasion): 5-year survival rate approximately 50-65%. Lymph node-positive disease carries a particularly poor prognosis.
• Stage IV (Distant metastases or tumor extending beyond Gerota fascia): 5-year survival rate approximately 12-15% historically, though outcomes are improving significantly with modern immunotherapy and targeted therapy combinations. Median overall survival with current first-line therapies now exceeds 40 months for favorable-risk patients.

Prognostic Models and Risk Stratification:

• IMDC (International Metastatic RCC Database Consortium) Criteria: For metastatic disease, risk groups are defined by Karnofsky performance status <80%, time from diagnosis to systemic therapy <1 year, anemia, hypercalcemia, neutrophilia, and thrombocytosis. Favorable (0 risk factors), intermediate (1-2), and poor (3+).
• UISS (UCLA Integrated Staging System): Combines TNM stage, Fuhrman grade, and ECOG performance status for localized and metastatic disease.
• SSIGN (Stage, Size, Grade, and Necrosis) Score: A validated prognostic tool for clear cell RCC incorporating tumor stage, size, nuclear grade, and histologic tumor necrosis.

Favorable Prognostic Factors: Clear cell histology (responsive to targeted therapy and immunotherapy), early stage at diagnosis, low Fuhrman nuclear grade (1-2), good performance status (ECOG 0-1), long disease-free interval before recurrence (>1 year), and absence of sarcomatoid or rhabdoid differentiation.

Unfavorable Prognostic Factors: Sarcomatoid dedifferentiation, non-clear cell histology (papillary type 2, collecting duct carcinoma, renal medullary carcinoma), elevated serum lactate dehydrogenase (LDH), hypercalcemia, anemia, neutrophilia, thrombocytosis, poor performance status, brain or liver metastases, and short time from nephrectomy to recurrence (<1 year).

Long-Term Follow-Up: After curative-intent treatment, surveillance typically includes periodic chest imaging and abdominal CT/MRI at intervals determined by risk of recurrence. Late recurrences (>5 years) can occur, particularly in clear cell RCC, necessitating prolonged follow-up beyond the standard 5-year surveillance period.

Precautions and Lifestyle Recommendations for Kidney Cancer Patients

Patients diagnosed with kidney cancer and those at elevated risk should observe the following precautions and self-care measures to optimize treatment outcomes and quality of life:

Adhere to Scheduled Follow-Up: Comply with the structured surveillance protocol recommended by your oncology team. Surveillance typically includes periodic imaging (CT, MRI, or ultrasound) and laboratory tests (complete blood count, comprehensive metabolic panel, LDH). The frequency depends on stage, histological subtype, and estimated risk of recurrence. Do not skip or delay follow-up appointments.

Smoking Cessation: If you smoke, immediate and complete cessation is critical. Smoking not only increases the risk of developing kidney cancer but also worsens treatment outcomes, increases surgical complications, reduces response to systemic therapy, and raises the risk of second primary malignancies. Seek smoking cessation counseling and pharmacotherapy if needed.

Blood Pressure Management: Monitor blood pressure regularly and maintain it within target ranges (<140/90 mmHg for most patients, or <130/80 mmHg for those with proteinuria or chronic kidney disease). Hypertension is both a risk factor and a potential consequence of kidney cancer treatment. Adhere to prescribed antihypertensive medications and adopt a low-sodium diet.

Healthy Weight Maintenance: Achieve and maintain a healthy body weight (BMI 18.5-24.9 kg/m2). Obesity is associated with worse outcomes in kidney cancer, and weight loss after diagnosis may improve survival. Work with a dietitian to develop a sustainable nutrition plan emphasizing plant-based foods, lean proteins, and whole grains while limiting processed foods and added sugars.

Kidney Function Protection: Patients with a solitary kidney following nephrectomy require diligent preservation of remaining renal function. Avoid nephrotoxic medications (NSAIDs such as ibuprofen, naproxen; certain antibiotics; intravenous contrast dye when alternatives exist). Stay well-hydrated (1.5-2 liters of water daily unless fluid-restricted). Report any changes in urination patterns, flank pain, or edema promptly.

Dietary Modifications: Adopt a kidney-friendly diet emphasizing fruits, vegetables, and whole grains. Limit red and processed meat consumption. Reduce sodium intake to <2,300 mg/day. Moderate protein intake based on kidney function status. Patients with impaired renal function should follow phosphorus and potassium restrictions as advised by a registered dietitian.

Physical Activity: Engage in regular moderate-intensity exercise (walking, swimming, cycling) for at least 150 minutes per week, as tolerated. Physical activity reduces cancer-related fatigue, improves quality of life, aids weight management, and may reduce the risk of recurrence. Adapt exercise intensity based on treatment phase and energy levels.

Medication Compliance and Caution: Take all prescribed medications as directed. Do not discontinue or modify doses without consulting your oncologist. Before starting any new medication (including over-the-counter drugs, supplements, or herbal products), consult your healthcare team, as some may interact with cancer therapies or affect kidney function.

Psychological and Emotional Well-Being: Cancer diagnosis and treatment impose significant emotional burden. Seek professional psychological counseling or join cancer support groups. Address anxiety, depression, and fear of recurrence proactively. Mindfulness-based stress reduction, meditation, and relaxation techniques may complement conventional psychological support.

Alcohol Moderation or Abstinence: Limit alcohol consumption to no more than one drink per day for women and two for men. Excessive alcohol intake is associated with increased cancer risk, liver stress during systemic therapy, and potential nephrotoxicity.

Infection Prevention During Treatment: During active systemic therapy (targeted therapy or immunotherapy), practice diligent hand hygiene, avoid close contact with individuals with active infections, stay current with recommended vaccinations (as approved by your oncologist), and report any signs of infection (fever >38°C, chills, productive cough, or urinary symptoms) promptly.

Sun Protection: Certain targeted therapies increase photosensitivity. Use broad-spectrum sunscreen (SPF 30+), wear protective clothing, and limit sun exposure during peak hours (10am-4pm).